Analyst Rating Update on Amarin Corporation PLC (AMRN)

Amarin Corporation PLC (AMRN) : 3 analysts are covering Amarin Corporation PLC (AMRN) and their average rating on the stock is 1, which is read as a Strong Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels.

Amarin Corporation PLC (AMRN) : Currently there are 3 street experts covering Amarin Corporation PLC (AMRN) stock. The most bullish and bearish price target for the stock is $10 and $4 respectively for the short term. The average price target of all the analysts comes to $6.5. The estimated standard deviation from the target is $3.28.

For the current week, the company shares have a recommendation consensus of Buy. Also, Jefferies initiates coverage on Amarin Corporation PLC (NASDAQ:AMRN). The shares have now been rated Buy by the stock experts at the ratings house. Jefferies announces the current price target of $3.5 per share on Amarin Corporation PLC. The rating by the firm was issued on May 12, 2016.


Amarin Corporation PLC (NASDAQ:AMRN): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $3.21 and $3.13 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $3.36. The buying momentum continued till the end and the stock did not give up its gains. It closed at $3.32, notching a gain of 4.40% for the day. The total traded volume was 15,311,588 . The stock had closed at $3.18 on the previous day.

Amarin Corporation plc (Amarin) is a biopharmaceutical company. The Company is engaged in the commercialization and development of therapeutics for cardiovascular health. Amarins lead product, Vascepa (icosapent ethyl) capsules, are used as an adjunct to diet to reduce triglyceride levels in adult patients with severe (triglyceride or TG over 500 milligrams per deciliter) hypertriglyceridemia. The Company sells Vascepa principally to various wholesalers, as well as regional wholesalers and specialty pharmacy providers, who in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. Vascepa is available in the United States by prescription only. Amarin is also developing Vascepa for the treatment of patients with high (TG over 200 milligrams per deciliter and less than 500 milligrams per deciliter) triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol (LDL-C) levels.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.